Diatherix and Color Genomics now carry both CLIA certification and CAP accreditation.
Researchers are hoping the 100,000-patient WISDOM study will lead to genetically informed breast cancer screening based on a woman's unique risk factors.
Color Genomics hopes its recently launched benefits program will enable a broader population to have access to breast and ovarian cancer risk testing.
The company offers a panel that analyzes 19 genes associated with breast and ovarian cancer, including BRCA1/2, for $249.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.